1. Blüher F, Hermansen K, Greenway F, et al. Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks. 51st EASD Annual Meeting 2015.
2. American Medical Association A. Declaration to classify obesity as a disease. Annual Meeting Report. 19 June 2013.
3. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9:88.
4. Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine. 2003; 138:24-32.
5. Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003; 32:869-894.
6. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373:1083-1096.
7. Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging. 2012; 37:730-732.
8. WHO. Obesity Data and Statistics (Europe). Available at: http://www.euro.who.int/en/health-topics/noncommunicable-dis... (Last accessed 21.08.15).
9. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry. 2000; 43:1664-1669.
10. EMA. Saxenda(R) (liraglutide 3 mg) Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... 80/WC500185786.pdf (Made available: 16 April 2015).
Further information
Media:
Katrine Sperling
+45-4442-6718
krsp@novonordisk.com
EmptyBreak:MARKER
Asa Josefsson
+45-3079-7708
aajf@novonordisk.com
EmptyBreak:MARKER
Investors:
Peter Hugreffe Ankersen
+45-3075-9085
phak@novonordisk.com
EmptyBreak:MARKER
Melanie Raouzeos
+45-3075-3479
mrz@novonordisk.com
EmptyBreak:MARKER
Daniel Bohsen
+45-3079-6376
dabo@novonordisk.com
EmptyBreak:MARKER
Frank Daniel Mersebach (US)
+1-609-235-8567
fdni@novonordisk.com
